Dr. Boothman is Professor of Biochemistry and Molecular Biology at Indiana University School of Medicine. He is a senior leader within the Indiana University Melvin and Bren Simon Cancer Center, serving as Associate Director for Translational Research and co-Director of the Experimental and Developmental Therapeutics (EDT) research program. Dr. Boothman is also the Sid and Lois Eskenazi Chair of Oncology. He is an elected representative for FASEB and is president-elect of the Society of Experimental Biology (SEBM). His current research projects include: (a) Use of NQO1 bioactivatable drugs for therapy of human solid NQO1+ cancers alone and with ionizing radiation (IR); (b) Use of NQO1 bioactivatable drugs to promote the tumor-selective use of DNA repair inhibitors, such as PARP inhibitors; and (c) Elucidating the roles of RNA termination factors in R-loop resolution, DSB repair defects, genetic instability and cancer vulnerabilities. His research is supported by four current NIH/NCI R01 awards, and an NIH U01 to support his radiation oncology research.

Dr. Boothman received his PhD in Microbiology and Immunology from the University of Miami Medical School, and completed his postdoctoral fellowship at Dana-Farber Cancer Institute of Harvard Medical School.

Posted Under: